OCUL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCUL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ocular Therapeutix's gross profit for the three months ended in Dec. 2023 was $13.42 Mil. Ocular Therapeutix's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $53.16 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Ocular Therapeutix's gross profit for the three months ended in Dec. 2023 was $13.42 Mil. Ocular Therapeutix's Revenue for the three months ended in Dec. 2023 was $14.80 Mil. Therefore, Ocular Therapeutix's Gross Margin % for the quarter that ended in Dec. 2023 was 90.64%.
Ocular Therapeutix had a gross margin of 90.64% for the quarter that ended in Dec. 2023 => Durable competitive advantage
During the past 12 years, the highest Gross Margin % of Ocular Therapeutix was 91.18%. The lowest was 45.00%. And the median was 84.90%.
The historical data trend for Ocular Therapeutix's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocular Therapeutix Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Gross Profit | Get a 7-Day Free Trial | 1.90 | 15.32 | 39.12 | 46.95 | 53.16 |
Ocular Therapeutix Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Gross Profit | Get a 7-Day Free Trial | 13.06 | 12.16 | 13.88 | 13.70 | 13.42 |
For the Biotechnology subindustry, Ocular Therapeutix's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Gross Profit distribution charts can be found below:
* The bar in red indicates where Ocular Therapeutix's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Ocular Therapeutix's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit (A: Dec. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 58.443 | - | 5.281 | |
= | 53.16 |
Ocular Therapeutix's Gross Profit for the quarter that ended in Dec. 2023 is calculated as
Gross Profit (Q: Dec. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 14.801 | - | 1.386 | |
= | 13.42 |
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $53.16 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Ocular Therapeutix's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as
Gross Margin % (Q: Dec. 2023 ) | = | Gross Profit (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 13.42 | / | 14.801 | |
= | 90.64 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ocular Therapeutix (NAS:OCUL) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ocular Therapeutix had a gross margin of 90.64% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Thank you for viewing the detailed overview of Ocular Therapeutix's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Summer Road Llc | 10 percent owner | 207 6TH STREET, WEST PALM BEACH FL 33401 |
Antony C. Mattessich | director | C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
Adrienne L Graves | director | 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558 |
Rabia Gurses Ozden | officer: Chief Medical Officer | C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210 |
Philip C. Strassburger | officer: General Counsel | 24 CROSBY DRIVE, BEDFORD MA 01730 |
Donald Notman | officer: Chief Financial Officer | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Christopher G White | officer: Chief Business Officer | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Jeffrey S. Heier | director | C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
Merilee Raines | director | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Lindstrom Richard L Md | director | 2811 WESTWOOD PL, WAYZATA MN 55391 |
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
Patricia Kitchen | officer: Chief Operations Officer | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Leslie J. Williams | director | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Seung Suh Hong | director | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Amarpreet Sawhney | director, 10 percent owner, officer: President and CEO | C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730 |
From GuruFocus
By sperokesalga sperokesalga • 06-05-2023
By Business Wire Business Wire • 06-01-2022
By sperokesalga sperokesalga • 04-14-2023
By Business Wire Business Wire • 11-08-2022
By Marketwired • 10-03-2023
By Marketwired • 10-24-2023
By Marketwired • 09-06-2023
By sperokesalga sperokesalga • 02-11-2023
By Marketwired • 08-07-2023
By sperokesalga sperokesalga • 06-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.